Literature DB >> 33749311

Associations Between HIV Serostatus and Cardiac Structure and Function Evaluated by 2-Dimensional Echocardiography in the Multicenter AIDS Cohort Study.

Henrique Doria de Vasconcellos1, Wendy S Post1,2, Ann-Margret Ervin2, Sabina Annette Haberlen2, Matthew Budoff3, Carlos Malvestutto4, Jared W Magnani5, Matthew J Feinstein6, Todd T Brown1, Joao A C Lima1, Katherine C Wu1.   

Abstract

Background We aimed to investigate whether there are differences in cardiac structure and systolic and diastolic function evaluated by 2-dimensional echocardiography among men living with versus without HIV in the era of combination antiretroviral therapy. Methods and Results We performed a cross-sectional analysis of 1195 men from MACS (Multicenter AIDS Cohort Study) who completed a transthoracic echocardiogram examination between 2017 and 2019. Associations between HIV serostatus and echocardiographic indices were assessed by multivariable regression analyses, adjusting for demographics and cardiovascular risk factors. Among men who are HIV+, associations between HIV disease severity markers and echocardiographic parameters were also investigated. Average age was 57.1±11.9 years; 29% of the participants were Black, and 55% were HIV+. Most men who were HIV+ (77%) were virally suppressed; 92% received combination antiretroviral therapy. Prevalent left ventricular (LV) systolic dysfunction (ejection fraction <50%) was low and HIV serostatus was not associated with left ventricular ejection fraction. Multivariable adjustment models showed that men who were HIV+ versus those who were HIV- had greater LV mass index and larger left atrial diameter and right ventricular (RV) end-diastolic area; lower RV function; and higher prevalence of diastolic dysfunction. Higher current CD4+ T cell count ≥400 cell/mm3 versus <400 was associated with smaller LV diastolic volume and RV area. Virally suppressed men who were HIV+ versus those who were HIV- had higher indexed LV mass and left atrial areas and greater diastolic dysfunction. Conclusions HIV seropositivity was independently associated with greater LV mass index, left atrial and RV sizes, lower RV function and diastolic abnormalities, but not left ventricular ejection fraction, which may herald a future predisposition to heart failure with preserved ejection fraction among men living with HIV.

Entities:  

Keywords:  HIV/AIDS; antiretroviral therapy; atria; cardiac remodeling; diastolic dysfunction; echocardiography; subclinical cardiovascular disease

Year:  2021        PMID: 33749311     DOI: 10.1161/JAHA.120.019709

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


  4 in total

Review 1.  The Role of Multimodality Imaging in HIV-Associated Cardiomyopathy.

Authors:  Ellise T Gambahaya; Rimsha Rana; Shashwatee Bagchi; Garima Sharma; Sudipa Sarkar; Erin Goerlich; Blanche Cupido; Monica Mukherjee; Allison G Hays
Journal:  Front Cardiovasc Med       Date:  2022-01-26

2.  Association of HIV Serostatus and Inflammation With Ascending Aortic Size.

Authors:  Anum S Minhas; Wendy S Post; Bin Liu; Henrique Doria De Vasconcellos; Sabina A Haberlen; Matthew Feinstein; Valentina Stosor; Matthew Budoff; Kara W Chew; Jared W Magnani; Todd Brown; Joao A C Lima; Katherine C Wu
Journal:  J Am Heart Assoc       Date:  2022-03-05       Impact factor: 5.501

3.  Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.

Authors:  Wendy S Post; Katherine C Wu; Tess E Peterson; Christian Landon; Sabina A Haberlen; Fiona Bhondoekhan; Michael W Plankey; Frank J Palella; Damani A Piggott; Joseph B Margolick; Todd T Brown
Journal:  BMC Cardiovasc Disord       Date:  2022-09-03       Impact factor: 2.174

4.  Diastolic dysfunction in people with HIV without known cardiovascular risk factors in Western Kenya.

Authors:  Bethel Woldu; Tecla M Temu; Nicholas Kirui; Bridgette Christopher; Samson Ndege; Wendy S Post; Jemima Kamano; Gerald S Bloomfield
Journal:  Open Heart       Date:  2022-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.